Message #13 From:
NewsBot Date: May 11, 2008 09:41:40 AM
Octillion Announces Streamlining of Key Process in Development of NanoPower Window Technology
Octillion Corp. (OTCBB: OCTL), an alternative energy technology
incubator, today announced efforts to streamline the deposition of
silicon nanoparticles on to glass, an important process in development
of the Company’s NanoPower Window technology,
a novel transparent window capable of generating electricity.
For the first time, while following previously established protocols for
producing lab-scale prototypes, a traditionally time-consuming and
cumbersome process for depositing nanoparticles on to glass has been
successfully replaced with a faster, more cost-effective,
commercially-available deposition technology. Octillion’s
NanoPower Window technology employs silicon nanoparticles that have the
potential to enable conventional home, office and industrial glass
windows to convert solar energy into electricity.
“This advancement allows us to speed-up one of
the most important steps in development of our NanoPower Window
technology, and certainly helps better prepare for the transition from
the lab towards larger-scale testing and production,”
explained Mr. Nicholas S. Cucinelli, President and CEO of Octillion
Corp. “This new ability to integrate
off-the-shelf components in the deposition process is promising and
indicative of a path towards building a lower-cost production technology.”
To date, manually-constructed, purpose-built, custom electrospray system
elements have been used for depositing nanoparticles on glass
substrates. Now these critical mechanical components have been
successfully replaced with less costly commercial components,
conventionally limited to use in the manufacture of powerful,
high-sensitivity chemical analytics instruments.
In the months ahead, the Company plans to further refine its proprietary
electrospray system, enhance quality control and consistent replication
of lab-scale samples, and continue efforts to identify, evaluate and
acquire additional strategic, enabling, and complementary technologies.
About Octillion Corp.
Through established relationships with universities, research
institutions and government agencies, we strive to identify technologies
and business opportunities on the leading edge of innovation that have
the potential of serving significant and unmet market needs. Once a
technology has been identified, we fund the research and development
activities relating to the technology with the intention of ultimately,
if warranted, licensing, commercializing and marketing the subject
technology, either through internal resources, collaborative agreements
or otherwise.
Unique to our business model is the use of established research
infrastructure owned by the various institutions we deal with, saving us
significant capital which would otherwise be required for such things as
land and building acquisition, equipment and furniture purchases, and
other incidental start up costs. As a result, we are able to benefit
from leading edge research while employing significantly less capital
than conventional organizations.
Among our current research and development activities is the development
of a technology that could adapt existing home and office glass windows
into those capable of generating electricity from solar energy without
losing significant transparency or requiring major changes in
manufacturing infrastructure. When thin films of silicon nanoparticles
are deposited (sprayed) onto silicon substrates, ultraviolet light is
absorbed and converted into electrical current. With appropriate
connections, the films act as nanosilicon photovoltaic solar cells that
convert solar radiation to electrical energy.
For additional information, please visit: www.Octillioncorp.com
To receive future press releases via email, please visit: http://www.Octillioncorp.com/alerts.php
To view the full HTML text of this release, please visit: http://Octillioncorp.com/OCTL_20080324.html
Legal Notice Regarding Forward-Looking
Statements
No statement herein should be considered an offer or a solicitation of
an offer for the purchase or sale of any securities. This release
contains forward-looking statements that are based upon current
expectations or beliefs, as well as a number of assumptions about future
events. Although Octillion Corp. (the “Company”
or “Octillion”)
believes that the expectations reflected in the forward-looking
statements and the assumptions upon which they are based are reasonable,
it can give no assurance that such expectations and assumptions will
prove to have been correct. Forward-looking statements, which involve
assumptions and describe our future plans, strategies, and expectations,
are generally identifiable by use of the words “may,”
“will,” “should,”
“could,” “expect,”
“anticipate,” “estimate,”
“believe,” “intend,”
or “project” or
the negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements are
subject to numerous factors and uncertainties, including but not limited
to adverse economic conditions, intense competition, lack of meaningful
research results, entry of new competitors and products, adverse
federal, state and local government regulation, inadequate capital,
unexpected costs and operating deficits, increases in general and
administrative costs, termination of contracts or agreements,
technological obsolescence of the Company's products, technical problems
with the Company's research and products, price increases for supplies
and components, litigation and administrative proceedings involving the
Company, the possible acquisition of new businesses or technologies that
result in operating losses or that do not perform as anticipated,
unanticipated losses, the possible fluctuation and volatility of the
Company's operating results, financial condition and stock price, losses
incurred in litigating and settling cases, dilution in the Company's
ownership of its business, adverse publicity and news coverage,
inability to carry out research, development and commercialization
plans, loss or retirement of key executives and research scientists,
changes in interest rates, inflationary factors, and other specific
risks. We currently have no commercial products intended to diagnose,
treat, prevent or cure any disease. The statements contained in this
press release regarding our on going research and development and the
results attained by us to-date have not been evaluated by the Food and
Drug Administration. There can be no assurance that further research and
development, and /or whether clinical trial results, if any, will
validate and support the results of our preliminary research and
studies. Further, there can be no assurance that the necessary
regulatory approvals will be obtained or that Octillion will be able to
develop commercially viable products on the basis of its technologies.
In addition, other factors that could cause actual results to differ
materially are discussed in the Company's most recent Form 10-QSB and
Form 10-KSB filings with the Securities and Exchange Commission. These
reports and filings may be inspected and copied at the Public Reference
Room maintained by the U.S. Securities & Exchange Commission at 100 F
Street, N.E., Washington, D.C. 20549. You can obtain information about
operation of the Public Reference Room by calling the U.S. Securities &
Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange
Commission also maintains an Internet site that contains reports, proxy
and information statements, and other information regarding issuers that
file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov.
The Company undertakes no obligation to publicly release the results of
any revisions to these forward looking statements that may be made to
reflect the events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events.
